Journal ArticleOPEN ACCESS

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

  • Ortiz Brugués A
  • Sibaud V
  • Herbault-Barrés B
  • et al.
The Oncologist (2020) 25(2) e391-e395
DOI: 10.1634/theoncologist.2019-0467
39Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Commenting on a recently published article on sicca syndrome linked to immune checkpoint inhibitor therapy, this letter to the editor shares another viewpoint on the management of this immune-related adverse event.

Cite

CITATION STYLE

APA

Ortiz Brugués, A., Sibaud, V., Herbault-Barrés, B., Betrian, S., Korakis, I., De Bataille, C., … Vigarios, E. (2020). Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending. The Oncologist, 25(2), e391–e395. https://doi.org/10.1634/theoncologist.2019-0467

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free